Download Your White Paper


Get Your White Paper On:

Novel Approaches to Immunotherapies and Immuno-Oncology

Download White Paper Here

The future is bright for antibody-based and cellular therapies for immuno-oncology, with the technologies of bispecifics and CAR-Ts converging. Bispecifics and CAR-Ts can be combined to create bispecific CAR-Ts. The technology is now not only limited to T-cells but is being applied to natural killer cells in the clinic. At the cutting-edge technologies such as TCR-T are targeting intracellular cancer epitopes. Antibodies alone can also be used to target intracellular proteins.

This whitepaper looks at the latest advances, technologies and challenges in immuno-oncology drug development, including:

  • CD3-Bispecifics vs CAR-T Cells
  • Bispecific or compound (cCAR-T) formats to overcome antigen escape
  • NanoCAR
  • CAR-NK and bispecific NK engagers, innately resistant to antigen escape
  • Autologous T-cells with enhanced TCR tumour antigen binding (SPEAR T-cells)
  • Targeting intracellular antigens such as RAS with antibodies

ABOUT THE AUTHOR:  David Orchard-Webb, PhD, is a freelance consultant and medical/biotech writer.

This piece represents the views of the author and not necessarily the views of KNect365 Life Sciences or the Antibody Therapeutics and Engineering conference series.

Fix the following errors: